A Phase II Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Melanoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide; Fludarabine; Interleukin-2; Tumour infiltrating lymphocytes
- Indications Malignant melanoma
- Focus Therapeutic Use
- 03 Jun 2013 Biomarkers information updated
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Aug 2012 Planned end date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov